

*Sub B1
Contd
A/C*

7.

(amended) Use of rivastigmine and excipients as defined in claim 1 in the manufacture of a medicament for the treatment of patients with mild to moderately severe Dementia of the Alzheimer's type by oral administration.

Use claims § 104 - 112, 2nd

REMARKS

Claims 3 to 7 have been amended to eliminate their multiple dependencies. In this connection, enclosed is an Appendix which represents a "marked-up" version of the changes made to Claims 3-7.

Favorable consideration of this application is respectfully requested.

Respectfully submitted,


George R. Dohmann
Attorney for Applicants
Reg. No. 33,593
(908) 522-6922

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

GRD/pk

Encl.: Appendix

Date: March 27, 2002

APPENDIX

(Marked-up Version of the Changes Made)

3. (amended) Pharmaceutical composition according to claim 1 or 2 wherein the outer film is permeable to water or body fluids.

4. (amended) Pharmaceutical composition according to any one of claims 1 to 3 wherein the coating has a thickness of 50 to 800 micrometers.

5. (amended) A pharmaceutical composition according to any one of claims 1 to 4 wherein said core releases an effective dose of the active agent 6 to 12 hours after ingestion.

6. (amended) A two pulse release pharmaceutical composition comprising a composition according to any one of claims 1 to 5.

7. (amended) Use of rivastigmine and excipients as defined in any one of claims 1 to 6 in the manufacture of a medicament for the treatment of patients with mild to moderately severe Dementia of the Alzheimer's type by oral administration.